Cryoport Agreement with Cryo Store BV Expands European Presence for its Best-in-Class Cryogenic Logistics Solutions

IRVINE, Calif., May 6, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Company"), the world's leading cryogenic logistics company, today announced that Cryo Store BV ("Cryo Store"), a European biostorage company, will utilize Cryoport's cryogenic logistics solutions to better serve the logistics needs of life sciences customers. Cryo Store provides storage and distribution services for temperature-controlled goods to biotechnology and pharmaceutical companies in Europe.

Cryoport, Inc. Logo.

Cryo Store will offer Cryoport's end-to-end cryogenic logistics solutions to pharmaceutical and biotechnology customers utilizing its biostorage services, in order to overcome the risks and challenges of shipping in liquid nitrogen containers along with complex logistics systems. Cryoport's purpose built cryogenic logistics solutions allow for the transportation of product without degradation of sample material. This ensures optimal sample usage and supports high quality research. Cryoport's best-in-class solution features a full range of integrated capabilities, including the Cryoportal logistics management platform, SmartPak II™ wireless condition monitoring system and signature Cryoport Express® dry vapor dewars. This collaboration ensures a smooth and on-time delivery of uniform samples, while adding to Cryo Store's business offering.

Menno René Sappé, Director, Cryo Store, commented, "We chose to partner with Cryoport because of their cold chain logistics expertise and proven ability to manage the challenges of transporting valuable, temperature-sensitive biological materials. Cryo Store is continuously handling and transporting such materials throughout Europe. As a result, we immediately see the benefit of Cryoport's specialized operating platform that employs industry-leading technology to ensure the timely and secure delivery of valuable samples. We are confident that Cryoport's assistance in the cold chain logistics space will be an unparalleled asset to our biostorage business."

Jerrell Shelton, Chief Executive Officer of Cryoport, Inc. stated, "Our partnership with Cryo Store marks yet another channel through which we are able to effectively support the cold chain market as the provider of the best-in-class cryogenic logistics solution.  Cryo Store's biostorage services play an indispensable link in the global cold chain for a number of pharma and biotech companies' biological material that is intended for clinical trials and patients throughout Europe."

About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. The Company provides leading edge logistics solutions for biologic materials, such as immunotherapies, stem cells, CAR-T cells and reproductive cells for clients worldwide. Cryoport actively supports points-of-care, CRO's, central laboratories, pharmaceutical companies, contract manufacturers and university researchers. For more information, visit

To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or Android mobile device.

Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company's business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2015. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Logo -


To view the original version on PR Newswire, visit:

SOURCE Cryoport, Inc.